Apatinib Mesylate
Phase 1UNKNOWN 1 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Subjects With Impaired Renal Function and Healthy Subjects
Conditions
Subjects With Impaired Renal Function and Healthy Subjects
Trial Timeline
Jun 5, 2020 → Apr 30, 2021
NCT ID
NCT04414852About Apatinib Mesylate
Apatinib Mesylate is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Subjects With Impaired Renal Function and Healthy Subjects. The current trial status is unknown. This product is registered under clinical trial identifier NCT04414852. Target conditions include Subjects With Impaired Renal Function and Healthy Subjects.
What happened to similar drugs?
6 of 16 similar drugs in Subjects With Impaired Renal Function and Healthy Subjects were approved
Approved (6) Terminated (1) Active (10)
Hype Score Breakdown
Clinical
6
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04414852 | Phase 1 | UNKNOWN |
| NCT04341090 | Phase 1 | Completed |
Competing Products
20 competing products in Subjects With Impaired Renal Function and Healthy Subjects